Company: CERO
Filing Date: 2025-12-05
Form Type: S-1
Source: 0001213900-25-118817
Chunk: 221

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-12-05
Form: S-1
Chunk 221
---
271 |   |     |            |   (668,087 | ) |     |            | (383.4 | )% |
| Net loss                                                   |     |                            |  (4,856,395 | ) |     |             | (4,227,967 | ) |     |            |   (628,428 | ) |     |            |   14.9 | %  |
| Deemed dividend on Series D Preferred Stock                |     |                            |  (6,649,828 | ) |     |             |          — |   |     |            | (6,649,828 | ) |     |            |  100.0 | %  |
| Net loss attributable to common stockholders               |     | $                          | (11,506,223 | ) |     | $           | (4,227,967 | ) |     | $          | (7,278,256 | ) |     |            |  172.1 | %  |

Research and Development Expenses Research and development expenses were $2,386,000 for the three months ended September 30, 2025 as compared to $1,774,000 for the three months ended September 30, 2024, reflecting an increase of $612,000. The increase was primarily attributable to an increase in clinical expenses of approximately $202,000, an increase in scientific consulting fees of $210,000, and an increase in drug manufacturing costs of $278,000, offset by a decrease in lab and other expenses of $19,000, a decrease in depreciation expense of $43,000 and a decrease in other research and development expenses of $16,000. During the first quarter of 2025, we began clinical trials related to the IND for CER-1236. The Company anticipates that its R&D expenses will significantly increase in the future as the Company increases headcount, compensation expense, and contracted services for preclinical and clinical development of its product candidates, as well as for manufacturing of clinical product to be used in clinical development. General and Administrative Expenses General and administrative expenses were $1,976,000 for the three months ended September 30, 2025 as compared to $2,628,000 for the three months ended September 30, 2024, reflecting a decrease of approximately $652,000. The decrease during the three months ended September 30, 2025 as compared to the three months ended September 30